Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Fig. 1

Illustration of the study protocol. The efficacy measures included IPSS, QOL score, OABSS, SHIM, UFM, and FVC at baseline and 4, 12, and 24 weeks after administration of tadalafil. Safety was evaluated based on the patient-reported adverse events during visits. IPSS, International Prostate Symptom Score; QOL, Quality of life; OABSS, overactive bladder symptom score; SHIM, sexual health inventory for men; UFM, uroflowmetry; FVC, frequency volume chart

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us